In this study, it was initially clarified that ERLIN2 is an anti-cancer factor and CDK5RAP3 is a pro-cancer factor in PCa, and that the expressions of both were significantly correlated with the clinic-pathologic features. This evidence concerns the gene ERLIN2 and cancer.